Glenmark Life Sciences releases Consolidated Quarterly Results for March 31, 2023. Glenmark Life Sciences has announced an increase in total income from Rs. 547.339 Crores as of December 31, 2022, to Rs. 624.156 Crores as of March 31, 2023. The net profit for the company has decreased from Rs. 104.993 Crores as of December 31, 2022, to Rs. 146.357 Crores as of March 31, 2023. However, the earnings per share (EPS) have improved, increasing from Rs. 8.57 on December 31, 2022, to Rs. 11.94 on March 31, 2023, according to the company’s statement.
Glenmark Life Sciences Quarterly Results (Q4 FY2023) – Quarter-over-Quarter Comparison:
Total income of the company is Rs. 624.156 Crores (March 31, 2023) vs. Rs. 547.339 Crores (December 31, 2022)
Net profit/loss: Rs. 146.357 Crores (March 31, 2023) vs. Rs. 104.993 Crores (December 31, 2022)
EPS: Rs. 11.94 (March 31, 2023) vs. Rs. 8.57 (December 31, 2022)
| Financials | Q4 FY2023 | Q3 FY2023 | % Change |
| Total Income | ₹ 624.156 Cr | ₹ 547.339 Cr | ⬆ 14.03% |
| Net Profit | ₹ 146.357 Cr | ₹ 104.993 Cr | ⬆ 39.40% |
| EPS | ₹ 11.94 | ₹ 8.57 | ⬆ 39.32% |
Glenmark Life Sciences Quarterly Results (Q4 FY2023) – Year-over-Year Comparison:
Total income of the company is Rs. 624.156 Crores (March 31, 2023) vs. Rs. 519.152 Crores (March 31, 2022)
Net profit/loss: Rs. 146.357 Crores (March 31, 2023) vs. Rs. 98.897 Crores (March 31, 2022)
EPS: Rs. 11.94 (March 31, 2023) vs. Rs. 8.07 (March 31, 2022)
| Financials | Q3 FY2023 | Q3 FY2022 | % Change |
| Total Income | ₹ 624.156 Cr | ₹ 519.152 Cr | ⬆ 20.23% |
| Net Profit | ₹ 146.357 Cr | ₹ 98.897 Cr | ⬆ 47.99% |
| EPS | ₹ 11.94 | ₹ 8.07 | ⬆ 47.96% |
Glenmark Life Sciences Quarterly Results (Year Ended FY2023) – Year-over-Year Comparison:
Total income of the company is Rs. 2190.177 Crores (March 31, 2023) vs. Rs. 2137.918 Crores (March 31, 2022)
Net profit/loss: Rs. 466.961 Crores (March 31, 2023) vs. Rs. 418.724 Crores (March 31, 2022)
EPS: Rs. 38.11 (March 31, 2023) vs. Rs. 35.63 (March 31, 2022)
| Financials | 12 Months Ended FY2023 | 12 Months Ended FY2022 | % Change |
| Total Income | ₹ 2190.177 Cr | ₹ 2137.918 Cr | ⬆ 2.44% |
| Net Profit | ₹ 466.961 Cr | ₹ 418.724 Cr | ⬆ 11.52% |
| EPS | ₹ 38.11 | ₹ 35.63 | ⬆ 6.96% |
Glenmark Life Sciences Share Dividend Announcement / Record Date:
The dividend’s record date has not yet come
About Glenmark Life Sciences:
Glenmark Life Sciences is a prominent producer and developer of specialized Active Pharmaceutical Ingredients (APIs) in chronic therapeutic fields that hold high value and are non-commoditized.
Download Full PDF Q4 Results Glenmark Life Sciences:
For More Latest News Click Here
